Why magnesium matters in perimenopause
Magnesium is involved in over 300 enzymatic reactions in the body. It plays a role in nerve function, muscle function, sleep regulation, energy metabolism and mood. During perimenopause, several of the symptoms women find most disruptive — poor sleep, anxiety, fatigue, muscle tension — have documented links to magnesium status.
Magnesium deficiency is common in the general population — estimated at around 15% in developed countries, and higher in women over 40 — but standard blood tests are a poor measure of true magnesium status. Most magnesium is stored intracellularly, so serum levels can appear normal even when cellular stores are depleted.
What the research shows
A 2012 randomised controlled trial found that magnesium supplementation significantly improved sleep quality, sleep time, and early morning awakening in older adults with insomnia. The mechanisms are well understood: magnesium regulates melatonin production and activates GABA receptors, which are involved in sleep onset and maintenance.
Magnesium plays a role in regulating the hypothalamic-pituitary-adrenal axis, which governs the stress response. Low magnesium is associated with increased anxiety and heightened stress reactivity. A 2017 systematic review found evidence that magnesium supplementation reduced anxiety in mildly anxious individuals.
Magnesium is essential for muscle relaxation and is involved in the regulation of calcium, which drives muscle contraction. It also works alongside calcium and Vitamin D in bone metabolism, supporting the mineralisation processes that maintain bone density.
Why the form matters
This is where most perimenopause supplements fail. The majority of magnesium supplements on the market use magnesium oxide — the cheapest form to manufacture. Magnesium oxide has a bioavailability of approximately 4%. The body absorbs almost none of it.
Magnesium bisglycinate — magnesium bound to the amino acid glycine — has significantly higher bioavailability. The glycine chelation allows the magnesium to pass through the intestinal wall more efficiently, and glycine itself has calming properties that complement the magnesium effect on sleep and anxiety.
The practical implication: a supplement listing 300mg of magnesium oxide is delivering approximately 12mg of bioavailable magnesium. A supplement listing 200mg of magnesium bisglycinate is delivering substantially more.
What dose is relevant
The UK reference nutrient intake for magnesium is 270mg per day for adult women. Most women do not reach this through diet alone. Therapeutic doses used in clinical studies on sleep and anxiety typically range from 200mg to 400mg of elemental magnesium per day in a bioavailable form.
What most supplements get wrong
Beyond the form issue, most perimenopause supplements that include magnesium make two additional errors. First, they underdose. Including 50mg of magnesium — even in a bioavailable form — is unlikely to produce meaningful clinical effect.
Second, they combine magnesium with calcium in the same supplement. Calcium and magnesium compete for absorption through the same intestinal transporters. Taking them together reduces the absorption of both. They are better taken separately and at different times of day.
The practical summary
• Magnesium plays a documented role in sleep quality, mood, muscle function and bone health — all relevant to perimenopause
• The form matters enormously — magnesium bisglycinate has significantly higher bioavailability than magnesium oxide
• Dose matters — sub-therapeutic doses are common and produce limited effect
• Magnesium and calcium should not be taken together